特发性多中心Castleman病:最新的诊断和治疗进展

IF 6.9 2区医学 Q1 HEMATOLOGY

Blood Reviews Pub Date : 2024-03-01 DOI:10.1016/j.blre.2023.101161

Evan Lang , Frits van Rhee

{"title":"特发性多中心Castleman病:最新的诊断和治疗进展","authors":"Evan Lang , Frits van Rhee","doi":"10.1016/j.blre.2023.101161","DOIUrl":null,"url":null,"abstract":"<div><p>Idiopathic multicentric Castleman disease (iMCD) is a rare disease, and it is likely underdiagnosed because of the heterogeneity of clinical manifestations and laboratory findings. While the disease leads to significant morbidity and mortality, its causes are not yet fully elucidated. There have been significant advances in diagnosis and treatment of iMCD in the past decade, including the approval of the anti-IL-6 antibody siltuximab. In this review, we provide an update of the many new developments and publications surrounding iMCD.</p></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"64 ","pages":"Article 101161"},"PeriodicalIF":6.9000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0268960X23001315/pdfft?md5=ccd844ecbcb062d737180f88229fb0ee&pid=1-s2.0-S0268960X23001315-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Idiopathic multicentric Castleman disease: An update in diagnosis and treatment advances\",\"authors\":\"Evan Lang , Frits van Rhee\",\"doi\":\"10.1016/j.blre.2023.101161\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Idiopathic multicentric Castleman disease (iMCD) is a rare disease, and it is likely underdiagnosed because of the heterogeneity of clinical manifestations and laboratory findings. While the disease leads to significant morbidity and mortality, its causes are not yet fully elucidated. There have been significant advances in diagnosis and treatment of iMCD in the past decade, including the approval of the anti-IL-6 antibody siltuximab. In this review, we provide an update of the many new developments and publications surrounding iMCD.</p></div>\",\"PeriodicalId\":56139,\"journal\":{\"name\":\"Blood Reviews\",\"volume\":\"64 \",\"pages\":\"Article 101161\"},\"PeriodicalIF\":6.9000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S0268960X23001315/pdfft?md5=ccd844ecbcb062d737180f88229fb0ee&pid=1-s2.0-S0268960X23001315-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Blood Reviews\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0268960X23001315\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0268960X23001315","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

特发性多中心Castleman病(iMCD)是一种罕见的疾病，由于临床表现和实验室结果的异质性，它可能被误诊。虽然这种疾病导致严重的发病率和死亡率，但其原因尚未完全阐明。在过去的十年里，iMCD的诊断和治疗取得了重大进展，包括抗il -6抗体siltuximab的批准。在这篇综述中，我们提供了许多关于iMCD的新发展和出版物的更新。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Idiopathic multicentric Castleman disease: An update in diagnosis and treatment advances

Idiopathic multicentric Castleman disease (iMCD) is a rare disease, and it is likely underdiagnosed because of the heterogeneity of clinical manifestations and laboratory findings. While the disease leads to significant morbidity and mortality, its causes are not yet fully elucidated. There have been significant advances in diagnosis and treatment of iMCD in the past decade, including the approval of the anti-IL-6 antibody siltuximab. In this review, we provide an update of the many new developments and publications surrounding iMCD.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Blood Reviews 医学-血液学

CiteScore

13.80

自引率

1.40%

发文量

期刊介绍： Blood Reviews, a highly regarded international journal, serves as a vital information hub, offering comprehensive evaluations of clinical practices and research insights from esteemed experts. Specially commissioned, peer-reviewed articles authored by leading researchers and practitioners ensure extensive global coverage across all sub-specialties of hematology.